Enclomiphene Direct

Compounded, not FDA-approved

Enclomiphene raised testosterone in every major trial. The ads stop there. The record does not.

This molecule went the whole distance: phase III trials against testosterone gel, an FDA filing, an advisory committee date. Then FDA cancelled the vote and issued a complete response letter, Europe refused it over missing symptom evidence and clot risk, and the company sold for 67 cents a share. Today the same trials sell it as a compounded product. We publish the trials with their numbers, the two regulatory endings, the isomer pharmacology that makes it genuinely interesting, and the approved 1967 sibling it competes with.

  • 48fetch-verified sources: 28 peer-reviewed, 20 government or registry
  • 21studies in the graded evidence table, species labeled on every row
  • 9primary regulatory documents quoted: FDA, EMA, Federal Register and SEC filings
  • 19cited rows across the vs-clomiphene and vs-TRT comparison tables

Online care, from intake to delivery

Enclomiphene care, made simple

Choose your plan, complete a private medical intake, and connect with a licensed provider. If prescribed, treatment ships discreetly to your door.

Enclomiphene care catalog product image
Compounded oral treatmentPrepared after approval
Catalog image. Dispensed product and packaging may vary by pharmacy.

Your care plan includes

Everything you need to get started

From$185.40per month
Licensed providerMedical reviewIf prescribedTreatment includedAt no added costDiscreet shippingWhen you need itOrder support
Choose your planChange or cancel future refills anytime
Due today$206.10then monthly

Encrypted checkout provider review required shipping included

  1. 01
    Choose your planSelect the supply and refill preference that works for you.
  2. 02
    Complete your intakeShare your health history in our private, secure flow.
  3. 03
    Provider reviewIf appropriate, your prescription is prepared and shipped.

Prescription treatment requires an online medical evaluation. A provider will determine whether treatment is medically appropriate; approval is not guaranteed.

Key facts

  • StatusCompounded, not FDA-approved
  • Half lifeAbout 7 hours for enclomiphene (serum half-life as cited in the published phase II report) hsource
  • Isomer contrastZuclomiphene half-life is measured in days vs hours for enclomiphene (FDA PCAC meeting material); the Clomid label reports detectable zuclomiphene beyond a month and label residue in feces 6 weeks after dosingsource
  • TmaxEnclomiphene tmax about 3 h vs zuclomiphene about 7 h after a single oral clomiphene dose hsource
  • Exposure asymmetrySingle 50 mg clomiphene dose: zuclomiphene AUC 1289 vs enclomiphene AUC 65 ng/mL x h; on chronic clomiphene 25 mg daily the serum zu:en ratio is about 20:1source
  • WashoutEnclomiphene washes out within days (5 half-lives is about 35 hours); zuclomiphene remained urine-detectable 121 to more than 261 days after 30 days of clomiphenesource
  • AbsorptionReadily absorbed orally in humans; excreted principally in feces (label pharmacokinetics for the mixed-isomer drug)source
  • MetabolismCYP2D6 is the primary enzyme metabolizing enclomiphene in vitro; quinidine abolished metabolism in human liver microsomessource
  • RouteOral capsules (12.5 mg and 25 mg were the strengths in the FDA-filed NDA); compounded products also sold as capsules and sublingual formssource
  • ClassSelective estrogen receptor modulator (SERM); trans-isomer of clomipheneReview or guidelinesource
  • Approved relativeClomiphene citrate (Clomid, NDA 016131, approved 1967, generics available), a 30-50% zuclomiphene mixtureRegulatory recordsource
  • FormOral (capsules; 12.5 mg and 25 mg in the filed NDA)Regulatory recordsource
  • US regulatory endingFDA Complete Response Letter, December 1, 2015 (NDA 207959 not approvable in its filed form)Regulatory recordsource
  • EU regulatory endingEMA CHMP refusal of EnCyzix (enclomifene), January 25, 2018Regulatory recordsource
  • Serum half-lifeAbout 7 hours (vs a zuclomiphene half-life measured in days)Human PKsource
  • Doses studied6.25, 12.5 and 25 mg daily in the Androxal programHuman trialsource
  • MoleculeC26H28ClNO, MW 406.0, CAS 15690-57-0 (PubChem CID 1548953)Chemical referencesource
  • Development codesAndroxal (Repros Therapeutics); earlier codes RMI 16,289 and ICI 46476; EU trade name EnCyzixChemical referencesource

Read the full Enclomiphene monograph

Browse by topic

Everything on enclomiphene, organized the way you research it.

All guides

65 in-depth, individually cited guides.

Review-gated archive: the guides below are preserved for individual medical and source review. They are excluded from search indexing and AI citation files.

Evidence 20 guides

Safety 15 guides

Sourcing 12 guides

Dosing 10 guides

Comparisons 8 guides

Follow the enclomiphene record as it changes

One short email when something real happens: FDA's compounding-list decision, a new trial, a safety action. Every item cited to its primary source.

Free. No spam, unsubscribe anytime. Your address is used for this brief and nothing else.

Start provider review